



Cancer Immunotherapy: Combinations

March 23–27, 2018 | Fairmont The Queen Elizabeth | Montreal, Quebec | Canada

Scientific Organizers:

Chris Boshoff, Pfizer Inc.

Lieping Chen, Yale University, USA

Lisa Coussens, Oregon Health & Science University, USA

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to the generous support from an anonymous donor

By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This meeting helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.

Session Topics:

- Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses
- Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations
- Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens
- Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors
- Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies
- Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion
- Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches
- Vaccines, Oncolytic Viruses and Cellular Therapies: Towards Combinations
- CTLA-4: Novel Molecules and Approaches to Combinations • HFrEF: Genetics and Epigenetics

Scholarship Application & Discounted Abstract Deadline: November 21, 2017

Abstract Deadline: December 19, 2017

Discounted Registration Deadline: January 16, 2018



Note: Scholarships are available for graduate students and postdoctoral fellows and are awarded based on the abstract submitted. Submitting an abstract is an excellent opportunity to gain exposure for your work. Abstracts submitted by the abstract deadline will also be considered for short talks on the program.

Upper image of killer T cells surrounding a cancer cell courtesy of Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths, National Institutes of Health

Meeting Hashtag: #KScancerimm
www.keystonesymposia.org/18C5

KEYSTONE SYMPOSIA[™]
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

Cancer Immunotherapy: Combinations (C5)

March 23-27, 2018 • Fairmont The Queen Elizabeth • Montreal, Québec, Canada

Scientific Organizers: Chris Boshoff, Lieping Chen and Lisa Coussens

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to the generous support from an anonymous donor.

Sponsored by AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology, Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: November 21, 2017 / Abstract Deadline: December 19, 2017 / Discounted Registration Deadline: January 16, 2018

FRIDAY, MARCH 23

Arrival and Registration

SATURDAY, MARCH 24

Welcome and Keynote Session

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Combination Treatment with SOC Checkpoint Inhibitors

Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapy Converts Pancreatic Cancers Into An Immunologic Disease

Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses

Lieping Chen, Yale University, USA
Design of Combination Therapy Based Adaptive Resistance Mechanisms in Tumor Microenvironment

Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy

Short Talk(s) Chosen from Abstracts

Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations

Short Talks Chosen from Abstracts

Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens

Speaker to be Announced

Andy Minn, University of Pennsylvania, USA
Interferon Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy

Bahija Jallal, MedImmune, Inc., USA
Combination Therapy for Cancer: Beyond Checkpoint Inhibition

Short Talk Chosen from Abstracts

Poster Session 1

SUNDAY, MARCH 25

Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors

Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions Between Myeloid and Lymphoid cells Regulate Response to Therapy in Solid Tumors

Judith A. Varner, University of California, San Diego, USA
Targeting Tissue Resident Macrophages and Their Progenitors To Suppress Cancer Progression

Chris H. Boshoff, Pfizer Inc., USA
Combining Checkpoint Inhibitors with Targeted Therapies

Jane L. Grogan, Genentech, Inc., USA
TIGIT and the PVR-Nectin Family Regulate Anti-Tumor Immunity

Short Talk(s) Chosen from Abstracts

Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies

Sergio A. Quezada, University College London, UK
Using Preclinical Models and Clinical Samples to Inform Rational Combinations

Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity

Bernard A. Fox, Earle A Chiles Research Institute, USA
Sequencing Checkpoint Therapies

Short Talk Chosen from Abstracts

Poster Session 2

MONDAY, MARCH 26

Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion

Peter S. Hammerman, Novartis Institutes for Biomedical Research, USA
Adaptive Resistance to Immune Checkpoint Blockade

Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Molecular and epigenetic programs defining tumor-specific T cell dysfunction

Gregory Lawrence Beatty, University of Pennsylvania, USA
Strategies for Incorporating CD40 Agonists in Cancer Therapy

Yong-Jun Liu, Sanofi, USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Overcoming T Cell Exclusion and an Immune-Privileged Microenvironment with Combination Approaches

Douglas T. Fearon, Cold Spring Harbor Laboratory, USA
CXCR4 Mediates Immune-Privilege in T Cell-Excluded Tumors

Daniela F. Quail, McGill University, Canada
Macrophage and T Cell Interactions in the Brain Tumor Microenvironment

Hiro Yoshi Nishikawa, National Cancer Center Japan, Japan
Control of Tumor-Associated Regulatory T Cells for Effective Cancer Immunotherapy

Short Talk Chosen from Abstracts

Poster Session 3

TUESDAY, MARCH 27

Vaccines, Oncolytic Viruses and Cellular Therapies: Towards Combinations

Stephen H. Thorne, University of Pittsburgh, USA
Oncolytic Viruses to Sensitize Resistant Tumors to Immunotherapy

Jeffrey Weber, NYU Langone Medical Center, USA
Clinical Efficacy and Biomarker Analyses in Patients receiving Adjuvant Checkpoint Blockade for Resected High-Risk Stages III/IV Melanoma

Olivera J. Finn, University of Pittsburgh School of Medicine, USA
Vaccines for prevention of non-viral cancers

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Combinations (C5)

March 23-27, 2018 • Fairmont The Queen Elizabeth • Montreal, Québec, Canada

Scientific Organizers: Chris Boshoff, Lieping Chen and Lisa Coussens

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to the generous support from an anonymous donor.

Sponsored by AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology, Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: November 21, 2017 / Abstract Deadline: December 19, 2017 / Discounted Registration Deadline: January 16, 2018

Gerald P. Linette, University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation

Short Talk(s) Chosen from Abstracts

CTLA-4: Novel Molecules and Approaches to Combinations

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Mario Sznol, Yale School of Medicine, USA
Lessons Learned from Anti-PD-1 and Anti-CTLA-4 Combinations

Alan J. Korman, Bristol-Myers Squibb, USA
Next Generation Anti-CTLA-4 Antibodies

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

WEDNESDAY, MARCH 28

Departure